Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
TAL Effectors for Genome Editing
TALEs Enable Rapid and Easy Design of Effectors to Control Gene Expression in Cells
- The ability to target a functional protein to a user-defined DNA sequence is a long-sought goal with the potential to enable genome engineering and genetic regulation of diverse cell types. Transcription activator–like effectors (TALE) proteins derived from the bacterial pathogen Xanthomonas have emerged as versatile scaffolds for engineering DNA-binding ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.